LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

Assertio Holdings Inc

Cerrado

0.72 2.86

Resumen

Variación precio

24h

Actual

Mínimo

0.71

Máximo

0.73

Métricas clave

By Trading Economics

Ingresos

-7.6M

-10M

Ventas

3M

32M

BPA

-0.03

Margen de beneficio

-32.552

Empleados

53

EBITDA

-8M

-3.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+295.83% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-12M

70M

Apertura anterior

-2.14

Cierre anterior

0.72

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Assertio Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 mar 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Global Business Travel Group Cuts Price of Deal for Rival CWT

22 mar 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

22 mar 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 mar 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

The $32 Billion Wizards Who Picked the Best Time to Start a Company: The Worst Time -- WSJ

21 mar 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar 2025, 22:15 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Unit Will Provide $185M to Rhodium on Deal Close >RIOT

21 mar 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Motion Filed to Approve Settlement in Rhodium's Bankruptcy Case

21 mar 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms Enters Non-Binding Term Sheet to Buy Certain Assets of Rhodium Encore >RIOT

21 mar 2025, 22:03 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- 4th Update

21 mar 2025, 21:05 UTC

Principales Noticias

The Score: Nvidia, Tesla, Nike and More Stocks That Defined the Week -- WSJ

21 mar 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

21 mar 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 mar 2025, 20:24 UTC

Principales Noticias

Major Indexes Stage Late Rally -- WSJ

21 mar 2025, 20:01 UTC

Principales Noticias

Columbia Yields to Trump in Battle Over Federal Funding -- WSJ

21 mar 2025, 19:40 UTC

Charlas de Mercado

Walmart's Beauty Marketplace Push Puts Ulta Beauty at Risk -- Market Talk

21 mar 2025, 19:29 UTC

Charlas de Mercado

Oil Futures Post Moderate Weekly Gains -- Market Talk

21 mar 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Grapple With $4 Level -- Market Talk

21 mar 2025, 19:02 UTC

Charlas de Mercado

Gold Eases to End Record-Setting Week -- Market Talk

21 mar 2025, 18:52 UTC

Charlas de Mercado

Telus Downgraded on Leverage, Cash Flow, Dividend Concerns -- Market Talk

21 mar 2025, 18:49 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Third Update

21 mar 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Aggressive Discounting Of Classics Could Damage Brand -- Market Talk

21 mar 2025, 18:07 UTC

Principales Noticias

Major Indexes Swing Around the Flatline -- WSJ

21 mar 2025, 18:07 UTC

Charlas de Mercado
Ganancias

Nike's Focus On Hot New Products May Not Offset Decline In Classic Styles -- Market Talk

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Nike's Turnaround Messaging May Add Some Confusion -- Market Talk

21 mar 2025, 17:41 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Second Update

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

21 mar 2025, 17:17 UTC

Charlas de Mercado

U.S. Oil Rig Count Slips By One to 486 -- Market Talk

21 mar 2025, 17:06 UTC

Charlas de Mercado

Bitcoin Treads Water After Trump Address -- Market Talk

21 mar 2025, 16:54 UTC

Charlas de Mercado
Ganancias

FedEx Assumed an Industrial Ramp Up That Didn't Come -- Market Talk

21 mar 2025, 16:40 UTC

Charlas de Mercado

Mexican Inflation Likely Slowed in Early March -- Market Talk

Comparación entre iguales

Cambio de precio

Assertio Holdings Inc Esperado

Precio Objetivo

By TipRanks

295.83% repunte

Estimación a 12 meses

Media 2.85 USD  295.83%

Máximo 3.5 USD

Mínimo 1.75 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Assertio Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.7099 / 0.7293Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Assertio Holdings Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.